Mariya I Meschaninova
Overview
Explore the profile of Mariya I Meschaninova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Meschaninova M, Novopashina D, Semikolenova O, Silnikov V, Venyaminova A
Molecules
. 2019 Nov;
24(23).
PMID: 31771111
A novel and convenient approach for the solid-phase 5'-functionalization of oligonucleotides is proposed in this article. The approach is based on the activation of free 5'-hydroxyl of polymer support-bound protected...
12.
Chernikov I, Gladkikh D, Meschaninova M, Karelina U, Venyaminova A, Zenkova M, et al.
Nucleic Acid Ther
. 2018 Dec;
29(1):33-43.
PMID: 30562146
The objective of this study was to analyze the effects of fluorophores on the intracellular accumulation and biological activity of small interfering RNA (siRNA) and its cholesterol conjugates. In this...
13.
Nuclease-resistant 63-bp trimeric siRNAs simultaneously silence three different genes in tumor cells
Gvozdeva O, Gladkih D, Chernikov I, Meschaninova M, Venyaminova A, Zenkova M, et al.
FEBS Lett
. 2017 Dec;
592(1):122-129.
PMID: 29197089
We designed a multimeric nuclease-resistant 63-bp trimeric small-interfering RNA (tsiRNA) comprising in one duplex the sequence of siRNAs targeting mRNAs of MDR1, LMP2, and LMP7 genes. We show that such...
14.
Chernikov I, Gladkikh D, Meschaninova M, Venyaminova A, Zenkova M, Vlassov V, et al.
Mol Ther Nucleic Acids
. 2017 Mar;
6:209-220.
PMID: 28325287
Chemical modifications are an effective way to improve the therapeutic properties of small interfering RNAs (siRNAs), making them more resistant to degradation in serum and ensuring their delivery to target...
15.
Gvozdeva O, Belogurov Jr A, Kuzina E, Gabibov A, Meschaninova M, Venyaminova A, et al.
Biochimie
. 2016 Mar;
125:75-82.
PMID: 26944796
The pathogenesis of autoimmune and neurodegenerative diseases involves overexpression of inducible subunits of the immunoproteasome. However, the clinical application of inhibitors to inducible subunits of the immunoproteasome has been limited...
16.
Kholodar S, Novopashina D, Meschaninova M, Venyaminova A
J Nucleic Acids
. 2014 Jan;
2013:860457.
PMID: 24455205
Here we report design, synthesis and characterization of highly sensitive, specific and stable in biological systems fluorescent probes for point mutation detection in DNA. The tandems of 3'- and 5'-mono-...
17.
Kabilova T, Meschaninova M, Venyaminova A, Nikolin V, Zenkova M, Vlassov V, et al.
Nucleic Acid Ther
. 2012 Apr;
22(3):196-204.
PMID: 22509928
Small interfering RNAs (siRNA) are able to activate the mammalian innate immune system depending on their structure, sequence, and method of delivery. The immunostimulatory activity of double-stranded RNA can be...
18.
Fokina A, Meschaninova M, Durfort T, Venyaminova A, Francois J
Biochemistry
. 2012 Feb;
51(11):2181-91.
PMID: 22352843
Insulin-like growth factor I (IGF-I) and its cognate receptor (IGF-1R) contribute to normal cell function and to tumorigenesis. The role of IGF-I signaling in tumor growth has been demonstrated in...
19.
Durfort T, Tkach M, Meschaninova M, Rivas M, Elizalde P, Venyaminova A, et al.
PLoS One
. 2012 Jan;
7(1):e29213.
PMID: 22235273
Insulin-like growth factor I (IGF-I) and its type I receptor (IGF-IR) play significant roles in tumorigenesis and in immune response. Here, we wanted to know whether an RNA interference approach...
20.
Petrova N, Chernikov I, Meschaninova M, Dovydenko I, Venyaminova A, Zenkova M, et al.
Nucleic Acids Res
. 2011 Nov;
40(5):2330-44.
PMID: 22080508
The conjugation of siRNA to molecules, which can be internalized into the cell via natural transport mechanisms, can result in the enhancement of siRNA cellular uptake. Herein, the carrier-free cellular...